NeurAxis to Host Third Quarter 2026 Results and Business Update Call on Monday, November 9, 2026
NeurAxis (NRXS) will report summarized third-quarter financial results before market open on November 9, 2026, and host a results call that day.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NeurAxis (NRXS) will report summarized third-quarter financial results before market open on November 9, 2026, and host a results call that day. The results cover the quarter ended September 30, 2026. The conference call is scheduled for 9:00 am ET to review the results and provide a business update.
Details
News Market Reaction – NRXS
On Oct 27, the day this news came out, NRXS closed 1.52% above the previous close. Our momentum scanner recorded 2 alerts for this stock that day.
Data tracked by StockTitan Argus for the Oct 27 session.
Key Figures
- Results reporting date
- November 9, 2026
- Q3 2026 summarized financial results; before market open
AI-generated analysis. How Rhea-AI works. Not financial advice.
CARMEL, Ind., Oct. 27, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its third quarter period ended September 30, 2026, on Monday, November 9, 2026, before market open. The Company has scheduled a conference call for the same day, Monday, November 9, 2026, at 9:00 am ET to review the results.
Conference Call Details
Date and Time: Monday, November 9, 2026, at 9:00am ET
Toll Free: 1-833-862-0272 (U.S. and Canada toll-free) International: 1-412-634-5915
Webcast: https://app.webinar.net/B2bPr8Dro8e
Replay: Toll Free: 1-855-669-9658 (U.S. and Canada toll-free) International: 1-412-317-0088
Replay access code: 9067695
Webcast: https://app.webinar.net/B2bPr8Dro8e
About NeurAxis, Inc.
NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of IB-Stim® , which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is FDA cleared for functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD), and FD-related nausea symptoms in patients 8 years and older. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway.
For more information, please visit http://neuraxis.com.
Investor Relations
Lytham Partners
Ben Shamsian
646-829-9701
shamsian@lythampartners.com
